Source: Registered Drug Product Database (NG) Publisher: Zolon Healthcare Limited, No 11 Town planning way, Ilupeju Lagos
Pharmacotherapeutic group: Antibacterials for systemic use, Third-generation cephalosporins
ATC code: J01DD04
Biophin inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
Bacterial resistance to Biophin may be due to one or more of the following mechanisms:
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
| Pathogen | Dilution Test (MIC, mg/L) | |
|---|---|---|
| Susceptible | Resistant | |
| Enterobacteriaceae | ≤1 | >2 |
| Staphylococcus spp | a. | a. |
| Streptococcus spp. (Groups A, B, C and G) | b. | b. |
| Streptococcus pneumoniae | ≤0.5c | >2 |
| Viridans group Streptococci | ≤0.5 | >0.5 |
| Haemophilus influenzae | ≤0.12c | >0.12 |
| Moraxella catarrhalis | ≤1 | >2 |
| Neisseria gonorrhoeae | ≤0.12 | >0.12 |
| Neisseria meningitidis | ≤0.12c | >0.12 |
| Non-species related | ≤1d | >2 |
a Susceptibility inferred from cefoxitin susceptibility.
b Susceptibility inferred from penicillin susceptibility.
c Isolates with a Biophin MIC above the susceptible breakpoint are rare and, if found, should be re-tested and, if confirmed, should be sent to a reference laboratory.
d Breakpoints apply to a daily intravenous dose of 1 g x 1 and a high dose of at least 2 g x 1.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of Biophin in at least some types of infections is questionable.
| Commonly susceptible species |
| Gram-positive aerobes Staphylococcus aureus (methicillin-susceptible)£ Staphylococci coagulase-negative (methicillin-susceptible)£ Streptococcus pyogenes (Group A) Streptococcus agalactiae (Group B) Streptococcus pneumoniae Viridans Group Streptococci Gram-negative aerobes Borrelia burgdorferi Haemophilus influenzae Haemophilus parainfluenzae Moraxella catarrhalis Neisseria gonorrhoea Neisseria meningitidis Proteus mirabilis Providencia spp Treponema pallidum |
| Species for which acquired resistance may be a problem |
| Gram-positive aerobes Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis+ Gram-negative aerobes Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli% Klebsiella pneumoniae% Klebsiella oxytoca% Morganella morganii Proteus vulgaris Serratia marcescens Anaerobes Bacteroides spp. Fusobacterium spp. Peptostreptococcus spp. Clostridium perfringens |
| Inherently resistant organisms |
| Gram-positive aerobes Enterococcus spp. Listeria monocytogenes Gram-negative aerobes Acinetobacter baumannii Pseudomonas aeruginosa Stenotrophomonas maltophilia Anaerobes Clostridium difficile Others: Chlamydia spp. Chlamydophila spp. Mycoplasma spp. Legionella spp. Ureaplasma urealyticum |
£ All methicillin-resistant staphylococci are resistant to Biophin.
+ Resistance rates >50% in at least one region
% ESBL producing strains are always resistant
Following intramuscular injection, mean peak plasma Biophin levels are approximately half those observed after intravenous administration of an equivalent dose. The maximum plasma concentration after a single intramuscular dose of 1 g is about 81 mg/l and is reached in 2-3 hours after administration.
The area under the plasma concentration-time curve after intramuscular administration is equivalent to that after intravenous administration of an equivalent dose.
After intravenous bolus administration of Biophin 500 mg and 1 g, mean peak plasma Biophin levels are approximately 120 and 200 mg/l respectively. After intravenous infusion of Biophin 500 mg, 1 g and 2 g, the plasma Biophin levels are approximately 80, 150 and 250 mg/l respectively.
The volume of distribution of Biophin is 7-12 l. Concentrations well above the minimal inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart, biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural, prostatic and synovial fluids. An 8-15% increase in mean peak plasma concentration (Cmax) is seen on repeated administration; steady state is reached in most cases within 48-72 hours depending on the route of administration.
Biophin penetrates the meninges. Penetration is greatest when the meninges are inflamed. Mean peak Biophin concentrations in CSF in patients with bacterial meningitis are reported to be up to 25% of plasma levels compared to 2% of plasma levels in patients with uninflamed meninges. Peak Biophin concentrations in CSF are reached approximately 4-6 hours after intravenous injection. Biophin crosses the placental barrier and is excreted in the breast milk at low concentrations (see section 4.6).
Biophin is reversibly bound to albumin. Plasma protein binding is about 95% at plasma concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising concentration (up to 85% at a plasma concentration of 300 mg/l).
Biophin is not metabolised systemically; but is converted to inactive metabolites by the gut flora.
Plasma clearance of total Biophin (bound and unbound) is 10-22 ml/min. Renal clearance is 5-12 ml/min. 50-60% of Biophin is excreted unchanged in the urine, primarily by glomerular filtration, while 40-50% is excreted unchanged in the bile. The elimination half-life of total Biophin in adults is about 8 hours.
In patients with renal or hepatic dysfunction, the pharmacokinetics of Biophin are only minimally altered with the half-life slightly increased (less than two fold), even in patients with severely impaired renal function.
The relatively modest increase in half-life in renal impairment is explained by a compensatory increase in non-renal clearance, resulting from a decrease in protein binding and corresponding increase in non-renal clearance of total Biophin.
In patients with hepatic impairment, the elimination half-life of Biophin is not increased, due to a compensatory increase in renal clearance. This is also due to an increase in plasma free fraction of Biophin contributing to the observed paradoxical increase in total drug clearance, with an increase in volume of distribution paralleling that of total clearance.
In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.
The half-life of Biophin is prolonged in neonates. From birth to 14 days of age, the levels of free Biophin may be further increased by factors such as reduced glomerular filtration and altered protein binding. During childhood, the half-life is lower than in neonates or adults.
The plasma clearance and volume of distribution of total Biophin are greater in neonates, infants and children than in adults.
The pharmacokinetics of Biophin are non-linear and all basic pharmacokinetic parameters, except the elimination half-life, are dose dependent if based on total drug concentrations, increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein binding and is therefore observed for total plasma Biophin but not for free (unbound) Biophin.
As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best correlation with in vivo efficacy is the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of Biophin for individual target species (i.e. %T > MIC).
There is evidence from animal studies that high doses of Biophin calcium salt led to formation of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be reversible. Animal studies produced no evidence of toxicity to reproduction and genotoxicity. Carcinogenicity studies on Biophin were not conducted.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.